Article Figures & Data
Figures
- Figure 1.
Time-course severity score of uremic xerosis in the study population (n = 99). *P < 0.001 (intragroup analysis).
- Figure 2.
Evolution of the severity of uremic pruritus under treatment in the study population (n = 99). *P < 0.0001 (intragroup analysis).
Tables
Variables n = 99 Age (years, mean ± SEM; range) 63.16 ± 1.28; 18–89 Gender (n, %) male 53 (54%) female 46 (46%) End-stage renal disease underlying disease (n, %) glomerular diseases 25 (25%) diabetic nephropathy 15 (15%) nephrosclerosis 15 (15%) polycystic kidney 14 (14%) congenital nephropathies 1 (1%) pyelonephritis 5 (5%) hypertensive nephropathy 7 (7%) others 9 (9%) unknown 10 (10%) Type of MRD (n, %) hemodialysis 90 (91%) peritoneal dialysis 9 (9%) Duration of MRD (years, mean ± SEM) 7.91 ± 0.71 Duration of xerosis (years, mean ± SEM) 5.4 ± 0.53 Clinical severity of xerosis (n, %) mild 2 (2%) moderate 50 (51%) severe to very severe 47 (47%) Total clinical score of xerosis (mean ± SEM) 8.3 ± 0.3 Association with pruritus (n, %) yes 74 (75%) no 25 (25%) Severity of pruritus (mm VAS, mean ± SEM) 40.64 ± 3.36 Quality of life scores (mean ± SEM) PCS 30.51 ± 1.21 MCS 41.29 ± 1.24 DLQI 5.61 ± 0.57 - Table 2.
Comparison of uremic xerosis severity on the lower legs between the two treatment groups after 7 days (Period I) in the study population (intent-to-treat analysis)
Study Parameters Test Product (n = 99) Comparator (n = 99) P Treatment response (n, %) yes 72 (73%) 44 (44%) <0.0001 no 27 (27%) 55 (56%) Instrumental severity of xerosis (arbitrary units, mean ± SEM) SURFT baseline 11.37 ± 0.64 10.25 ± 0.55 day 7 3.19 ± 0.42 5.35 ± 0.57 <0.0001 MOD baseline 19.20 ± 0.98 18.02 ± 0.76 day 7 7.83 ± 0.60 11.56 ± 0.93 <0.0001 Test side preference clearly better 60 13 <0.0001 comparable 26 26
In this issue
Randomized, Double-blind Study with Glycerol and Paraffin in Uremic Xerosis
